Fact Based List:
KFF: Top 10 Drugs Accounting for 22% of Medicare Part D Total Gross Spending in 2021
Submitted by Charlene Ice on Fri, 07/14/2023 - 12:50
- Eliquis (a blood thinner): $12.6B
- Revlimid (a treatment for multiple myeloma): $5.9B
- Xarelto (a blood thinner): $5.2B
- Trulicity (a diabetes drug): $4.7B
- Januvia (a diabetes drug): $4.1B
- Jardiance (a diabetes drug): $3.7B
- Imbruvica (a cancer treatment): $3.2B
- Humira (Cf) Pen (a treatment for rheumatoid arthritis and other conditions): $2.9B
- Lantus Solostar (a diabetes drug): $2.8B
- Ozempic (a diabetes drug): $2.6B
Notes: Total gross spending on all Medicare Part D prescription drug products was $216 billion in 2021, not accounting for rebates. B: billion.
Source: KFF, July 12, 2023
Source URL: https://www.kff.org/medicare/issue-brief/a-small-number-of-d...
Printer-friendly version
Send to friend| List Ratings: |
Lists You Might Also Be Interested In
- KFF: 7 Ways Dual-Eligibles Received Their Medicare Coverage in 2020
- Five States with the Most Eligible for Medicare Advantage
- Health Pocket: The Bottom Five Providers In Overall Customer Service For Medicare Advantage
- Percent Distribution of Supplemental Medicare Coverage Type for Income Range of $20,001 to $30,000
- Martine G. Brousse: Five problems with Medicare Part C
Login or register to post comments
